-
Twitch sparks gamers' wrath with Amazon AI sharing deal
-
Tielemans apologises for offending Villa fans with Man Utd boast
-
Blaze forces families to abandon Turkish tour boat
-
Stocks gain as US inflation worries ease, oil slips
-
'If you can, move!' say Rome's viral dancing seniors
-
Heavy rain soaks eastern Japan, prompting highest-level warning
-
Zambia voters weigh Hichilema's economic record
-
Celtic boss O'Neill 'much better' after hospital procedure
-
SBCFX to Showcase Trading Innovation, Regional Growth Strategy, and Future Vision at iFX EXPO Asia 2026
-
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
-
Hodgkinson sets up Werro showdown after Euro 800m drama
-
Maghreb sees demographic shift with fertility at historic low
-
'How many will die?': the mysterious ailment killing Kenyan elephants
-
European stocks gain as oil prices ease
-
Arteta coy over Lewis-Skelly's Arsenal future after 'emotional' celebration
-
Infantino future should be decided by election says African football chief
-
Romania shuts down nuclear plant as Danube drops
-
Man City star Doku signs five-year contract extension
-
German steel giant Thyssenkrupp weighs options as Rhine drops
-
Fabien Barthez joins Zidane's new France coaching setup
-
US ambassador denounces settler siege as Israel dispatches troops
-
Taiwan chokes mobile internet speeds in drill for Chinese attack
-
Hasan takes 6-55 as Bangladesh claim opening day of Australia Test
-
From Chinese AI to Global ETFs: STARTRADER Launches 45 New 24/7 Stock and ETF CFDs
-
Taiwan says AI agents used in cyberattacks targeting island
-
Tech stocks enjoy rebound after US inflation on mixed day for markets
-
Japan protests Putin's first visit to disputed islands
-
Hasan takes 6-55 as Bangladesh bundle out Australia for 198
-
Kiss wants fit-again Wallabies playmaker Gordon to 'open up' Japan
-
Swiatek sinks Svitolina to set up Rybakina title clash in Toronto
-
British eccentrics push humble garden shed to new heights
-
Australia's Pallister shines, mixed relay record falls as Pan Pacs open
-
Zambia votes with president's economic record on the line
-
Hasan puts Bangladesh in charge as Australia struggle to 183-8
-
Germany's dry rivers spark battle on engineering vs restoration
-
Putin visits Kuril islands claimed by Japan
-
Senators demand inquiry into conditions aboard USS Abraham Lincoln
-
Swiatek downs Svitolina to reach first WTA final of 2026
-
All Blacks' Proctor out of South Africa series, Mo'unga called up
-
Jones says Japan 'watching videos of geese' for Australia clash
-
Bangladesh quick Hasan reduces Australia to 74-4 at lunch
-
Bloodied but unbowed, defending champ Shelton reaches Montreal final
-
Seoul tech leads Asian stock gains as traders cheer US inflation
-
Wallabies make eight changes for return Japan Test
-
Farage and Count Binface go head-to-head in snap UK poll
-
Messi returns after father's death but Miami knocked out of Leagues Cup
-
Afghan students divided over smartphone ban at universities
-
Outflanked by AI, stars fade for South Korea's blind fortune-tellers
-
Japan go back to school for second Australia Test
-
Venezuela govt, opposition wrap up round of post-Maduro talks
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
N.Walker--AT